시장보고서
상품코드
1987703

의약품 개발 서비스 시장 보고서(2026년)

Drug Development Services Global Market Report 2026

발행일: | 리서치사: 구분자 The Business Research Company | 페이지 정보: 영문 250 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

의약품 개발 서비스 시장 규모는 최근 빠르게 확대하고 있습니다. 2025년 280억 9,000만 달러에서 2026년에는 315억 달러로, CAGR 12.2%로 성장할 것으로 전망됩니다. 지난 수년간의 성장 요인으로는 제약사의 R&D 투자 확대, 의약품 개발 서비스 아웃소싱 증가, 만성질환 및 감염성 질환의 유병률 증가, 규제 준수 요건 강화, 분자생물학 및 체외시험의 발전 등을 꼽을 수 있습니다.

의약품 개발 서비스 시장 규모는 향후 몇 년간 급속한 성장이 전망됩니다. 2030년에는 502억 6,000만 달러에 달하고, CAGR은 12.4%를 기록할 전망입니다. 예측 기간의 성장 요인으로는 AI와 머신러닝의 도입, 바이오의약품 및 맞춤의료 파이프라인의 확대, CRO(임상시험수탁기관)에 대한 수요 증가, 클라우드 기반 임상 데이터 관리의 통합, 신흥 시장에서의 의약품 개발 서비스 성장 등을 꼽을 수 있습니다. 예측 기간의 주요 동향으로는 전임상 연구 확대, 의약품 규제 대응 최적화, 의약품 안전성 모니터링 강화, 임상 데이터 관리 서비스 성장, 품질 보증 및 컴플라이언스 서비스 강화 등을 꼽을 수 있습니다.

정밀의료 및 맞춤의료에 대한 관심이 높아지면서 향후 의약품 개발 서비스 시장의 성장을 견인할 것으로 예상됩니다. 정밀의료와 맞춤의료는 환자의 유전자 프로필, 임상적 특징, 특정 질병 상태에 따라 치료와 개입을 맞춤화하는 의료 접근법을 말합니다. 보다 정확한 진단과 표적 치료의 선택을 가능하게 하는 유전체 기술의 발전으로 정밀의료와 맞춤의료에 대한 관심이 높아지고 있습니다. 의약품 개발 서비스는 특정 유전적, 분자적, 환자 관련 질병 요인에 대한 표적 치료제의 설계, 시험 및 검증을 촉진하여 정밀의료 및 맞춤형 의료를 실현합니다. 예를 들어, 2024년 2월 미국 기반의 비영리 단체인 개인화된 의학 연합(Personalized Medicine Coalition)은 2023년 FDA가 희귀 질환에 대한 16개의 새로운 맞춤형 치료법을 승인했다고 보고했습니다. 이는 2022년 승인 건수 6건에 비해 크게 증가한 수치입니다. 따라서 정밀의료 및 맞춤의료에 대한 관심이 높아지면서 의약품 개발 서비스 시장의 성장을 견인하고 있습니다.

의약품 개발 서비스 시장의 주요 기업들은 초기 단계의 제제 개발을 효율화하고 복잡한 약물 후보물질의 시장 출시 시간을 단축하기 위해 과학 기반 제제 개발 가속화 플랫폼과 같은 혁신적인 솔루션 개발에 집중하고 있습니다. 과학 주도형 제제 개발 가속화 플랫폼은 표적화된 기술과 체계화된 프로토콜을 적용하여 의약품 제제를 신속하게 최적화하여 임상시험으로 진행하는 통합 개발 프로그램입니다. 예를 들어, 2025년 5월 독일에 본사를 둔 제약회사 Aenova Group GmbH는 특히 파이프라인에서 진행하기 어려운 난용성 화합물을 대상으로 의약품 제제의 초기 개발을 가속화하기 위한 'Aenovation' 프로그램을 시작했습니다. 이 프로그램은 종합적인 API 프로파일링 및 개발 가능성 분류, 용해도 향상 기술을 이용한 신속한 제형 개발 및 시제품 선정, 그리고 GMP 실험실 및 파일럿 규모 생산으로의 원활한 전환이라는 3단계 접근 방식을 채택하여 초기부터 적절한 결과와 인체 임상 1상 시험용 물질을 보다 신속하게 제공합니다. 시험용 물질을 보다 신속하게 제공합니다. Aenovation 프로그램은 생체이용률과 관련된 중요한 문제를 해결하고 효율적인 제제 전략을 가능하게함으로써 바이오테크 스타트업을 포함한 제약 혁신가들이 혁신적인 치료법을 보다 신속하고 자원 효율적으로 임상 단계에 진입할 수 있도록 돕고 있습니다.

자주 묻는 질문

  • 의약품 개발 서비스 시장 규모는 어떻게 변화하고 있나요?
  • 의약품 개발 서비스 시장의 성장 요인은 무엇인가요?
  • 정밀의료와 맞춤의료가 의약품 개발 서비스 시장에 미치는 영향은 무엇인가요?
  • 의약품 개발 서비스 시장의 주요 기업들은 어떤 혁신적인 솔루션을 개발하고 있나요?
  • Aenova Group GmbH의 'Aenovation' 프로그램은 어떤 목적을 가지고 있나요?

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의가 공급망에 미치는 영향, 코로나가 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계의 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 시장에서 세계의 총 잠재 시장 규모(TAM)

제9장 시장 세분화

제10장 지역별·국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자 환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업과 혁신적 기업

제38장 세계의 시장 경쟁 벤치마킹과 대시보드

제39장 시장에 등장 예정 스타트업

제40장 주요 인수합병

제41장 시장 잠재력이 높은 국가, 부문, 전략

제42장 부록

KSM

Drug development services refer to specialized services that support the discovery, testing, regulatory approval, and commercialization of new pharmaceutical and biotechnology products. Its purpose is to accelerate the development of safe and effective drugs, reduce time-to-market, and ensure compliance with regulatory standards.

The primary types of drug development services include drug metabolism and pharmacokinetics, biological services, and medicinal chemistry. Drug metabolism and pharmacokinetics involve the study of how drugs are absorbed, distributed, metabolized, and excreted in the body, providing essential data for safe and effective drug development. These services support processes such as candidate validation, lead optimization, hit-to-lead identification, target validation, and target selection. They are applied across drug types including biologics, infectious disease diagnostics, and small molecules. The therapeutic areas covered include cardiovascular disease, digestive system disease, immune system and infectious diseases, neurology, oncology, and other therapeutic areas, and they are used by end users such as pharmaceutical companies, biotechnology companies, contract research organizations, and academic and research institutes.

Tariffs have influenced the drug development services market by increasing the cost of imported laboratory equipment, reagents, and specialized chemicals essential for preclinical and clinical testing. The impact is most pronounced on drug metabolism, medicinal chemistry, and biological services segments, particularly in regions like North America and Europe that rely on imported materials. Some domestic service providers benefit from the shift toward local sourcing, creating opportunities for regional CROs and research institutes to expand service offerings.

The drug development services market size has grown rapidly in recent years. It will grow from $28.09 billion in 2025 to $31.5 billion in 2026 at a compound annual growth rate (CAGR) of 12.2%. The growth in the historic period can be attributed to growth in r&d investments by pharma companies, increase in outsourcing of drug development services, rising prevalence of chronic and infectious diseases, stricter regulatory compliance requirements, advancements in molecular biology and in vitro testing.

The drug development services market size is expected to see rapid growth in the next few years. It will grow to $50.26 billion in 2030 at a compound annual growth rate (CAGR) of 12.4%. The growth in the forecast period can be attributed to adoption of ai and machine learning in drug discovery, expansion of biologics and personalized medicine pipelines, increasing demand for contract research organizations, integration of cloud-based clinical data management, growth in emerging markets for drug development services. Major trends in the forecast period include preclinical research expansion, regulatory affairs optimization, pharmacovigilance enhancement, clinical data management services growth, quality assurance and compliance services strengthening.

The growing emphasis on precision and personalized medicine is expected to drive the growth of the drug development services market going forward. Precision and personalized medicine refers to a healthcare approach that customizes medical treatments and interventions based on patients' genetic profiles, clinical characteristics, and specific disease conditions. The focus on precision and personalized medicine is increasing due to advancements in genomic technologies that allow more accurate diagnosis and targeted treatment selection. Drug development services enable precision and personalized medicine by facilitating the design, testing, and validation of targeted therapies tailored to specific genetic, molecular, and patient-related disease factors. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 new personalized treatments for rare diseases in 2023, compared with six approvals in 2022. Therefore, the growing emphasis on precision and personalized medicine is driving the growth of the drug development services market.

Leading companies in the drug development services market are focusing on developing innovative solutions, such as science-driven formulation acceleration platforms, to streamline early-stage drug formulation and reduce time-to-market for complex drug candidates. Science-driven formulation acceleration platforms are integrated development programs that apply targeted technologies and structured protocols to rapidly optimize drug formulations and advance them toward clinical testing. For example, in May 2025, Aenova Group GmbH, a Germany-based pharmaceutical company, launched the Aenovation program to accelerate the early development of pharmaceutical formulations, especially for poorly soluble compounds that are challenging to progress through the pipeline. The program uses a three-step approach, including comprehensive API profiling and developability classification, rapid formulation and prototype selection using solubility enhancement technologies, and seamless transfer to GMP lab and pilot-scale manufacturing to deliver right-first-time results and materials for first-in-human trials more quickly. By addressing critical bioavailability challenges and enabling efficient formulation strategies, the Aenovation program helps pharma innovators, including biotech start-ups, bring innovative therapies closer to clinical phases with greater speed and resource efficiency.

In September 2025, Symeres B.V., a Netherlands-based pharmaceutical company, acquired DGr Pharma for an undisclosed amount. Through this acquisition, Symeres expanded its early-phase drug development services and regulatory expertise to offer a more integrated end-to-end development platform for biopharmaceutical clients. DGr Pharma is a Netherlands-based firm providing consulting and operational support for early-stage pharmaceutical development.

Major companies operating in the drug development services market are IQVIA Holdings Inc., Labcorp Drug Development, Lonza Group AG, SGS Life Sciences, ICON plc, Eurofins Scientific SE, PPD Inc., Syneos Health Inc., WuXi AppTec Co. Ltd., Catalent Inc., Charles River Laboratories International Inc., Parexel International Corporation, Samsung Biologics Co. Ltd., Medpace Holdings Inc., PRA Health Sciences Inc., Fujifilm Diosynth Biotechnologies, Recipharm AB, PCI Pharma Services Inc., Almac Group Limited, Evotec SE, Aenova Group GmbH, Rentschler Biopharma SE, BioReliance Corporation, Covance SE

North America was the largest region in the drug development services market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug development services market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the drug development services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The drug development services market includes revenues earned by entities through the preclinical research services, in vitro testing services, toxicology and safety assessment, clinical data management, biostatistics services, regulatory affairs and submission support, pharmacovigilance services, and quality assurance and compliance services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The drug development services market research report is one of a series of new reports from The Business Research Company that provides drug development services market statistics, including drug development services industry global market size, regional shares, competitors with a drug development services market share, detailed drug development services market segments, market trends and opportunities, and any further data you may need to thrive in the drug development services industry. This drug development services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Drug Development Services Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses drug development services market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on end user analysis.
  • Benchmark performance against key competitors based on market share, innovation, and brand strength.
  • Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for drug development services ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The drug development services market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
  • The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
  • The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
  • The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
  • The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
  • The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

  • Markets Covered:1) By Type: Drug Metabolism And Pharmacokinetics; Biological Services; Medicinal Chemistry
  • 2) By Process: Candidate Validation; Lead Optimization; Hit To Lead Identification; Target Validation; Target Selection
  • 3) By Drug: Biologics; Infectious Disease Diagnostics; Small Molecules
  • 4) By Therapeutic Area: Cardiovascular Disease; Digestive System Disease; Immune System And Infectious Disease; Neurology; Oncology; Other Therapeutic Areas
  • 5) By End User: Pharmaceutical Companies; Biotechnology Companies; Contract Research Organizations; Academic And Research Institutes
  • Subsegments:
  • 1) By Drug Metabolism And Pharmacokinetics: Absorption Studies; Distribution Studies; Metabolism Studies; Excretion Studies; Bioavailability Assessment; Drug Drug Interaction Studies
  • 2) By Biological Services: Cell Based Assays; Molecular Biology Services; Protein Expression And Purification; Biomarker Discovery; In Vitro Pharmacology
  • 3) By Medicinal Chemistry: Compound Design And Synthesis; Structure Activity Relationship Studies; Lead Optimization Chemistry; Chemical Library Development; Process Chemistry Development
  • Companies Mentioned: IQVIA Holdings Inc.; Labcorp Drug Development; Lonza Group AG; SGS Life Sciences; ICON plc; Eurofins Scientific SE; PPD Inc.; Syneos Health Inc.; WuXi AppTec Co. Ltd.; Catalent Inc.; Charles River Laboratories International Inc.; Parexel International Corporation; Samsung Biologics Co. Ltd.; Medpace Holdings Inc.; PRA Health Sciences Inc.; Fujifilm Diosynth Biotechnologies; Recipharm AB; PCI Pharma Services Inc.; Almac Group Limited; Evotec SE; Aenova Group GmbH; Rentschler Biopharma SE; BioReliance Corporation; Covance SE
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: Word, PDF or Interactive Report
  • + Excel Dashboard
  • Added Benefits
  • Bi-Annual Data Update
  • Customisation
  • Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

  • 1.1. Key Market Insights (2020-2035)
  • 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
  • 1.3. Major Factors Driving the Market
  • 1.4. Top Three Trends Shaping the Market

2. Drug Development Services Market Characteristics

  • 2.1. Market Definition & Scope
  • 2.2. Market Segmentations
  • 2.3. Overview of Key Products and Services
  • 2.4. Global Drug Development Services Market Attractiveness Scoring And Analysis
    • 2.4.1. Overview of Market Attractiveness Framework
    • 2.4.2. Quantitative Scoring Methodology
    • 2.4.3. Factor-Wise Evaluation
  • Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
    • 2.4.4. Market Attractiveness Scoring and Interpretation
    • 2.4.5. Strategic Implications and Recommendations

3. Drug Development Services Market Supply Chain Analysis

  • 3.1. Overview of the Supply Chain and Ecosystem
  • 3.2. List Of Key Raw Materials, Resources & Suppliers
  • 3.3. List Of Major Distributors and Channel Partners
  • 3.4. List Of Major End Users

4. Global Drug Development Services Market Trends And Strategies

  • 4.1. Key Technologies & Future Trends
    • 4.1.1 Biotechnology, Genomics & Precision Medicine
    • 4.1.2 Artificial Intelligence & Autonomous Intelligence
    • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
    • 4.1.4 Industry 4.0 & Intelligent Manufacturing
    • 4.1.5 Immersive Technologies (Ar/Vr/Xr) & Digital Experiences
  • 4.2. Major Trends
    • 4.2.1 Preclinical Research Expansion
    • 4.2.2 Regulatory Affairs Optimization
    • 4.2.3 Pharmacovigilance Enhancement
    • 4.2.4 Clinical Data Management Services Growth
    • 4.2.5 Quality Assurance And Compliance Services Strengthening

5. Drug Development Services Market Analysis Of End Use Industries

  • 5.1 Pharmaceutical Companies
  • 5.2 Biotechnology Companies
  • 5.3 Contract Research Organizations
  • 5.4 Academic And Research Institutes
  • 5.5 Medical Research Laboratories

6. Drug Development Services Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Drug Development Services Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

  • 7.1. Global Drug Development Services PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 7.2. Global Drug Development Services Market Size, Comparisons And Growth Rate Analysis
  • 7.3. Global Drug Development Services Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
  • 7.4. Global Drug Development Services Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Drug Development Services Total Addressable Market (TAM) Analysis for the Market

  • 8.1. Definition and Scope of Total Addressable Market (TAM)
  • 8.2. Methodology and Assumptions
  • 8.3. Global Total Addressable Market (TAM) Estimation
  • 8.4. TAM vs. Current Market Size Analysis
  • 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Drug Development Services Market Segmentation

  • 9.1. Global Drug Development Services Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Drug Metabolism And Pharmacokinetics, Biological Services, Medicinal Chemistry
  • 9.2. Global Drug Development Services Market, Segmentation By Process, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Candidate Validation, Lead Optimization, Hit To Lead Identification, Target Validation, Target Selection
  • 9.3. Global Drug Development Services Market, Segmentation By Drug, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Biologics, Infectious Disease Diagnostics, Small Molecules
  • 9.4. Global Drug Development Services Market, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Cardiovascular Disease, Digestive System Disease, Immune System And Infectious Disease, Neurology, Oncology, Other Therapeutic Areas
  • 9.5. Global Drug Development Services Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations, Academic And Research Institutes
  • 9.6. Global Drug Development Services Market, Sub-Segmentation Of Drug Metabolism And Pharmacokinetics, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Absorption Studies, Distribution Studies, Metabolism Studies, Excretion Studies, Bioavailability Assessment, Drug Drug Interaction Studies
  • 9.7. Global Drug Development Services Market, Sub-Segmentation Of Biological Services, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Cell Based Assays, Molecular Biology Services, Protein Expression And Purification, Biomarker Discovery, In Vitro Pharmacology
  • 9.8. Global Drug Development Services Market, Sub-Segmentation Of Medicinal Chemistry, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Compound Design And Synthesis, Structure Activity Relationship Studies, Lead Optimization Chemistry, Chemical Library Development, Process Chemistry Development

10. Drug Development Services Market Regional And Country Analysis

  • 10.1. Global Drug Development Services Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • 10.2. Global Drug Development Services Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Drug Development Services Market

  • 11.1. Asia-Pacific Drug Development Services Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 11.2. Asia-Pacific Drug Development Services Market, Segmentation By Type, Segmentation By Process, Segmentation By Drug, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Drug Development Services Market

  • 12.1. China Drug Development Services Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 12.2. China Drug Development Services Market, Segmentation By Type, Segmentation By Process, Segmentation By Drug, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Drug Development Services Market

  • 13.1. India Drug Development Services Market, Segmentation By Type, Segmentation By Process, Segmentation By Drug, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Drug Development Services Market

  • 14.1. Japan Drug Development Services Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 14.2. Japan Drug Development Services Market, Segmentation By Type, Segmentation By Process, Segmentation By Drug, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Drug Development Services Market

  • 15.1. Australia Drug Development Services Market, Segmentation By Type, Segmentation By Process, Segmentation By Drug, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Drug Development Services Market

  • 16.1. Indonesia Drug Development Services Market, Segmentation By Type, Segmentation By Process, Segmentation By Drug, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Drug Development Services Market

  • 17.1. South Korea Drug Development Services Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 17.2. South Korea Drug Development Services Market, Segmentation By Type, Segmentation By Process, Segmentation By Drug, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Drug Development Services Market

  • 18.1. Taiwan Drug Development Services Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 18.2. Taiwan Drug Development Services Market, Segmentation By Type, Segmentation By Process, Segmentation By Drug, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Drug Development Services Market

  • 19.1. South East Asia Drug Development Services Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 19.2. South East Asia Drug Development Services Market, Segmentation By Type, Segmentation By Process, Segmentation By Drug, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Drug Development Services Market

  • 20.1. Western Europe Drug Development Services Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 20.2. Western Europe Drug Development Services Market, Segmentation By Type, Segmentation By Process, Segmentation By Drug, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Drug Development Services Market

  • 21.1. UK Drug Development Services Market, Segmentation By Type, Segmentation By Process, Segmentation By Drug, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Drug Development Services Market

  • 22.1. Germany Drug Development Services Market, Segmentation By Type, Segmentation By Process, Segmentation By Drug, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Drug Development Services Market

  • 23.1. France Drug Development Services Market, Segmentation By Type, Segmentation By Process, Segmentation By Drug, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Drug Development Services Market

  • 24.1. Italy Drug Development Services Market, Segmentation By Type, Segmentation By Process, Segmentation By Drug, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Drug Development Services Market

  • 25.1. Spain Drug Development Services Market, Segmentation By Type, Segmentation By Process, Segmentation By Drug, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Drug Development Services Market

  • 26.1. Eastern Europe Drug Development Services Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 26.2. Eastern Europe Drug Development Services Market, Segmentation By Type, Segmentation By Process, Segmentation By Drug, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Drug Development Services Market

  • 27.1. Russia Drug Development Services Market, Segmentation By Type, Segmentation By Process, Segmentation By Drug, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Drug Development Services Market

  • 28.1. North America Drug Development Services Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 28.2. North America Drug Development Services Market, Segmentation By Type, Segmentation By Process, Segmentation By Drug, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Drug Development Services Market

  • 29.1. USA Drug Development Services Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 29.2. USA Drug Development Services Market, Segmentation By Type, Segmentation By Process, Segmentation By Drug, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Drug Development Services Market

  • 30.1. Canada Drug Development Services Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 30.2. Canada Drug Development Services Market, Segmentation By Type, Segmentation By Process, Segmentation By Drug, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Drug Development Services Market

  • 31.1. South America Drug Development Services Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 31.2. South America Drug Development Services Market, Segmentation By Type, Segmentation By Process, Segmentation By Drug, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Drug Development Services Market

  • 32.1. Brazil Drug Development Services Market, Segmentation By Type, Segmentation By Process, Segmentation By Drug, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Drug Development Services Market

  • 33.1. Middle East Drug Development Services Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 33.2. Middle East Drug Development Services Market, Segmentation By Type, Segmentation By Process, Segmentation By Drug, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Drug Development Services Market

  • 34.1. Africa Drug Development Services Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 34.2. Africa Drug Development Services Market, Segmentation By Type, Segmentation By Process, Segmentation By Drug, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Drug Development Services Market Regulatory and Investment Landscape

36. Drug Development Services Market Competitive Landscape And Company Profiles

  • 36.1. Drug Development Services Market Competitive Landscape And Market Share 2024
    • 36.1.1. Top 10 Companies (Ranked by revenue/share)
  • 36.2. Drug Development Services Market - Company Scoring Matrix
    • 36.2.1. Market Revenues
    • 36.2.2. Product Innovation Score
    • 36.2.3. Brand Recognition
  • 36.3. Drug Development Services Market Company Profiles
    • 36.3.1. IQVIA Holdings Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.2. Labcorp Drug Development Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.3. Lonza Group AG Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.4. SGS Life Sciences Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.5. ICON plc Overview, Products and Services, Strategy and Financial Analysis

37. Drug Development Services Market Other Major And Innovative Companies

  • Eurofins Scientific SE, PPD Inc., Syneos Health Inc., WuXi AppTec Co. Ltd., Catalent Inc., Charles River Laboratories International Inc., Parexel International Corporation, Samsung Biologics Co. Ltd., Medpace Holdings Inc., PRA Health Sciences Inc., Fujifilm Diosynth Biotechnologies, Recipharm AB, PCI Pharma Services Inc., Almac Group Limited, Evotec SE

38. Global Drug Development Services Market Competitive Benchmarking And Dashboard

39. Upcoming Startups in the Market

40. Key Mergers And Acquisitions In The Drug Development Services Market

41. Drug Development Services Market High Potential Countries, Segments and Strategies

  • 41.1 Drug Development Services Market In 2030 - Countries Offering Most New Opportunities
  • 41.2 Drug Development Services Market In 2030 - Segments Offering Most New Opportunities
  • 41.3 Drug Development Services Market In 2030 - Growth Strategies
    • 41.3.1 Market Trend Based Strategies
    • 41.3.2 Competitor Strategies

42. Appendix

  • 42.1. Abbreviations
  • 42.2. Currencies
  • 42.3. Historic And Forecast Inflation Rates
  • 42.4. Research Inquiries
  • 42.5. The Business Research Company
  • 42.6. Copyright And Disclaimer
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제